elacridar and plx4032
elacridar has been researched along with plx4032 in 3 studies
Compound Research Comparison
| Studies (elacridar) | Trials (elacridar) | Recent Studies (post-2010) (elacridar) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
|---|---|---|---|---|---|
| 284 | 8 | 119 | 1,657 | 103 | 1,587 |
Protein Interaction Comparison
| Protein | Taxonomy | elacridar (IC50) | plx4032 (IC50) |
|---|---|---|---|
| Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Beijnen, JH; Durmus, S; Schinkel, AH; Sparidans, RW; Wagenaar, E | 1 |
| Henderson, CJ; MacLeod, AK; McLaughlin, LA; Wolf, CR | 1 |
Other Studies
3 other study(ies) available for elacridar and plx4032
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Topics: Acridines; Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Blood-Brain Barrier; Drug Combinations; Female; Humans; Indoles; Kidney; Madin Darby Canine Kidney Cells; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Sulfonamides; Tetrahydroisoquinolines; Tissue Distribution; Vemurafenib | 2012 |
Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models.
Topics: Acridines; Animals; Biological Availability; Biological Transport; Cell Line, Tumor; Constitutive Androstane Receptor; Cytochrome P-450 CYP3A; Female; Indoles; Male; Melanoma; Mice; Mice, Knockout; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Sulfonamides; Tetrahydroisoquinolines; Vemurafenib | 2015 |